Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK)
inhibitor that was approved by the FDA for the treatment of renal cell ...
SUTENT® (sunitinib malate) for treatment of advanced renal cell carcinoma,
gastrointestinal stromal tumors & advanced pancreatic NET. Risk info for
Trade Name: Sutent <sup>®</sup> Other Name: SU11248. Drug Type: Sunitinib is a targeted
therapy and is a receptor protein-tyrosine kinase inhibitor. It inhibits the actions ...
Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor
receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and ...
Sunitinib is an indolinone derivative and tyrosine kinase inhibitor with potential
antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular ...
May 16, 2007 ... Sunitinib is metabolized primarily by the cytochrome P450 enzyme, CYP3A4, to
produce its primary active metabolite, which is further ...
Easy to read patient leaflet for sunitinib. Includes indications, proper use, special
instructions, precautions, and possible side effects.
Jan 13, 2016 ... Sunitinib (Sutent®) is an oral multikinase inhibitor used in the treatment of some
types of gastrointestinal stromal tumors, renal cell cancers and ...
Find out more about sunitinib (also called Sutent®), which may be used to treat a
type of kidney cancer called renal cell carcinoma (RCC), gastrointestinal ...
Mar 10, 2015 ... SUTENT, an oral multi-kinase inhibitor, is the malate salt of sunitinib. Sunitinib
malate is described chemically as Butanedioic acid, hydroxy-, ...